Compare Neurocrine Biosciences Inc (NBIX) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs NIO Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while NIO Inc. trades at $3.65 (market cap $9.23B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| NBIX | NIO | |
|---|---|---|
Market Cap | $15.77B | $9.23B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $7.89 |
52-Week Low | $123.10 | $3.70 |
Enterprise Value | $15.78B | $7.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
NIO trades at $3.79, down 0.26% over 24 hours, with a bearish technical signal but improving fundamentals. Recent Q2 2026 earnings beat expectations with a narrower loss, while revenue grew 69.1% year-over-year to $4.74 billion (Seeking Alpha, 2026-09-03). The stock faces headwinds from a weak Chinese EV market but shows progress toward profitability with positive operating cash flow in Q2.
The outlook is mixed: analyst consensus is bullish with a $5.50 price target (50% buy ratings), but risks include high debt, competition, and macroeconomic pressures. Upside depends on sustained delivery growth and margin expansion, while downside risks loom from cost inflation and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
